Empowering induction therapy for locally advanced head and neck cancer

Annals of Oncology

Volumn 22, Issue 4, 2011, Pages 773-781

  Argiris, A ^a   Karamouzis, M V ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Cetuximab; Docetaxel; Induction therapy; Locally advanced head and neck cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; GEFITINIB; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; INTERLEUKIN 6; LAPATINIB; PACLITAXEL; VASCULOTROPIN;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG RESPONSE; DRUG TOLERABILITY; DYSPHAGIA; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; HEAD AND NECK CANCER; HUMAN; HYPOMAGNESEMIA; LETHARGY; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; REVIEW; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA;

EID: 79953322627     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq426     Document Type: Review

References (52)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008; 371: 1695-1709.
3. Pignon JP, le MA, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4-14.
4. Argiris A, Jayaram P, Pichardo D. Revisiting induction chemotherapy for head and neck cancer. Oncology (Williston Park) 2005; 19: 759-770.
5. Domenge C, Hill C, Lefebvre JL et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer 2000; 83: 1594-1598.
6. Zorat PL, Paccagnella A, Cavaniglia G et al. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst 2004; 96: 1714-1717.
7. Lefebvre JL, Chevalier D, Luboinski B et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst 1996; 88: 890-899.
8. Janinis J, Papadakou M, Panagos G et al. Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer. Am J Clin Oncol 2001; 24: 227-231.
9. Posner MR, Glisson B, Frenette G et al. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 2001; 19: 1096-1104.
10. Schrijvers D, van HC, Kerger J et al. Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study. Ann Oncol 2004; 15: 638-645.
11. Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357: 1705-1715.
12. Vermorken JB, Remenar E, van HC et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357: 1695-1704.
13. Pointreau Y, Garaud P, Chapet S et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009; 101: 498-506.
14. Hitt R, Lopez-Pousa A, Martinez-Trufero J et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005; 23: 8636-8645.
15. Hitt R, Grau JJ, Lopez-Pousa A et al. Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC). J Clin Oncol 2009; 27(15s): 6009 Abstr.
16. Paccagnella A, Ghi MG, Loreggian L et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Ann Oncol 2010; 21: 1515-1522.
17. Chung CH, Ely K, McGavran L et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006; 24: 4170-4176.
18. Rubin GJ, Melhem MF, Gooding WE et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90: 824-832.
19. Karamouzis MV, Grandis JR, Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 2007; 298: 70-82.
20. Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127.
21. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamouscell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
22. Haddad RI, Tishler RB, Norris C et al. Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27: 4448-4453.
23. Mesia R, Vazquez S, Grau JJ et al. A single-arm phase II trial to evaluate the combination of cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (TPF) as induction chemotherapy (IC) in patients (pts) with unresectable SCCHN. J Clin Oncol 2009; 27(15s): 6015 Abstr.
24. Argiris AE, Gibson MK, Heron DE et al. Phase II trial of neoadjuvant docetaxel (T), cisplatin (P), and cetuximab (E) followed by concurrent radiation (X), P, and E in locally advanced head and neck cancer (HNC). J Clin Oncol 2008; 26(15s): 6002 Abstr.
25. Salama JK, Stenson KM, Kistner EO et al. Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. Ann Oncol 2008; 19: 1787-1794.
26. Kies MS, Holsinger FC, Lee JJ et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol 2010; 28: 8-14.
27. Wanebo HJ, Ghebremichael M, Burtness B et al. Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG, E2303). J Clin Oncol 2007; 25 (18s): 6015 Abstr.
28. Cohen EE, Haraf DJ, Stenson KM et al. Integration of gefitinib (G), into a concurrent chemoradiation (CRT) regimen followed by G adjuvant therapy in patients with locally advanced head and neck cancer (HNC)-a phase II trial. J Clin Oncol 2005; 23(16s): 5506 Abstr.
29. Herchenhorn D, Dias FL, Pineda RM et al. Phase II study of erlotinib combined with cisplatin and radiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2007; 25(18s): 6033 Abstr.
30. Pfister DG, Lee NY, Sherman E et al. Phase II study of bevacizumab (B) plus cisplatin (C) plus intensity-modulated radiation therapy (IMRT) for locoregionally advanced head and neck squamous cell cancer (HNSCC): preliminary results. J Clin Oncol 2009; 27(15s): 6013 Abstr.
31. Savvides P, Greskovich J, Bokar JA et al. Phase II study of bevacizumab with docetaxel and radiation in locally advanced head and neck squamous cell cancer. J Clin Oncol 2008; 26 (15s): 6071 Abstr.
32. Hainsworth JD, Spigel DR, Burris HA III et al. Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck. Cancer 2009; 115: 2138-2146.
33. Specenier PM, Lalami Y, Vermorken J et al. EORTC 24051: unexpected side effects of a phase I study of TPF induction chemotherapy (IC) followed by chemoradiation (CRT) with lapatinib (LAP), a dual EGFR/ErbB2 inhibitor, in patients with locally advanced larynx and hypopharynx squamous cell carcinoma (LA-LxHxSCC). J Clin Oncol 2009; 27(15s): 6017 Abstr.
34. Meluch AA, Spigel D, Burris HA et al. Combined modality therapy with radiation therapy (RT), chemotherapy, bevacizumab, and erlotinib in the treatment of patients (pts) with locally advanced squamous carcinoma of the head and neck. J Clin Oncol 2009; 27(15s): 6012 Abstr.
35. Fortin A, Bairati I, Albert M et al. Effect of treatment delay on outcome of patients with early-stage head-and-neck carcinoma receiving radical radiotherapy. Int J Radiat Oncol Biol Phys 2002; 52: 929-936.
36. Hoffstetter S, Marchal C, Peiffert D et al. Treatment duration as a prognostic factor for local control and survival in epidermoid carcinomas of the tonsillar region treated by combined external beam irradiation and brachytherapy. Radiother Oncol 1997; 45: 141-148.
37. Duncan W, MacDougall RH, Kerr GR et al. Adverse effect of treatment gaps in the outcome of radiotherapy for laryngeal cancer. Radiother Oncol 1996; 41: 203-207.
38. Lefebvre J, Pointreau Y, Rolland F et al. Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): preliminary results of the randomized phase II TREMPLIN study. J Clin Oncol 2009; 27(15s): 6010 Abstr.
39. Brockstein B, Haraf DJ, Rademaker AW et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol 2004; 15: 1179-1186.
40. Cullen KJ, Schumaker L, Nikitakis N et al. β-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial. J Clin Oncol 2009 in press.
41. Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-1810.
42. Khambata-Ford S, Harbison CT, Hart LL et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 918-927.
43. Licitra L, Rolland F, Bokemeyer C et al. Biomarker potential of EGFR gene copy number by FISH in the phase III EXTREME study: platinum-based CT plus cetuximab in first-line R/M SCCHN. J Clin Oncol 2009; 27(15s): 6005 Abstr.
44. Ferris RL, Feinstein T, Grandis J et al. Serum biomarkers as predictors of clinical outcome after cetuximab-based therapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2009; 27(15s): 6035 Abstr.
45. Byers LA, Kies MS, William WN et al. Profiling of cytokines and angiogenic factors (C/AF) in head and neck (HN) cancer correlates circulating biomarkers with clinical outcomes following induction chemotherapy. J Clin Oncol 2008; 26(15s): 6005 Abstr.
46. Ang KK, Harris J, Wheeler R et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
47. Rischin D, Young R, Fisher R et al. Prognostic significance of HPV and p16 status in patients with oropharyngeal cancer treated on a large international phase III trial. J Clin Oncol 2009; 27(15s): 6004 Abstr.
48. Worden FP, Kumar B, Lee JS et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol 2008; 26: 3138-3146.
49. Barringer DA, Hutcheson KA, Sturgis EM et al. Effect of induction chemotherapy on speech and swallowing function in patients with oral tongue cancer. Head Neck 2009; 31: 611-617.
50. Chu K, Wehrli B, Wiebe E et al. Can HPV-related tonsillar squamous cell carcinoma (TSCC) be treated with radiation alone? Int J Radiat Oncol Biol Phys 2009; 75(1 (3 Suppl): 2462 Abstr.
51. Urba S, Wolf G, Eisbruch A et al. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol 2006; 24: 593-598.
52. Urba SG, Moon J, Giri PG et al. Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: a Southwest Oncology Group Trial. J Clin Oncol 2005; 23: 88-95.